Immunotherapy boost for hard-to-treat bowel cancer?

NCT ID NCT06733038

Recruiting now Disease control Sponsor: Gruppo Oncologico del Nord-Ovest Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy (FOLFOXIRI) and bevacizumab helps people with a specific type of metastatic colorectal cancer live longer without their disease getting worse. The study enrolls 238 adults whose tumors have a certain immune profile (Immunoscore IC-high) and are not mismatch repair deficient. The main goal is to see if the combination delays cancer progression compared to chemotherapy alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab (an immunotherapy drug) added to standard chemotherapy (FOLFOXIRI) and bevacizumab
What this could lead to: If successful, this could offer a new first-line treatment option that delays cancer progression for people with a specific type of metastatic colorectal cancer.
What could go wrong: This is a Phase 3 trial, but it only includes patients with a specific immune profile (Immunoscore IC-high). Adding immunotherapy may increase side effects, and it is not yet known if it will meaningfully improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Locations

AOU Careggi
RECRUITING

Florence, FI, 50134, Italy
ASL di Viterbo
RECRUITING

Viterbo, VT, 01100, Italy
Azienda Ospedaliera Card. G. Panico
RECRUITING

Tricase, LE, 73039, Italy
Azienda Ospedaliera Universitaria Luigi Vanvitelli
RECRUITING

Naples, 80131, Italy
Azienda Ospedaliero Universitaria Policlinico Rodolico - S. Marco
RECRUITING

Catania, CT, 95123, Italy
Azienda Ospedaliero Universitaria di Modena
RECRUITING

Modena, MO, 41124, Italy
Azienda Sanitaria Universitaria Friuli Centrale
RECRUITING

Udine, UD, 33100, Italy
Azienda USL Toscana Nord Ovest
RECRUITING

Livorno, LI, 57124, Italy
Azienda USL della Romagna
RECRUITING

Ravenna, RA, 48121, Italy
Azienda Usl di Piacenza
RECRUITING

Piacenza, 29121, Italy
Fondazione Casa Sollievo della Sofferenza
RECRUITING

San Giovanni Rotondo, FG, 71013, Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
RECRUITING

Milan, MI, 20122, Italy
Fondazione IRCCS INT - Milano
RECRUITING

Milan, MI, 20133, Italy
Fondazione Poliambulanza, Istituto Ospedaliero
RECRUITING

Brescia, BS, 25124, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
RECRUITING

Roma, RM, 00168, Italy
IRCCS Centro di Riferimento Oncologico
RECRUITING

Aviano, PN, 33081, Italy
IRCCS Istituto Nazionale Tumori "Fondazione Giovanni Pascale"
RECRUITING

Naples, 80131, Italy
Istituto Oncologico Veneto Irccs
RECRUITING

Padova, PD, 35128, Italy
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
RECRUITING

Meldola, FC, 47014, Italy
Nuovo Ospedale di Prato S. Stefano
RECRUITING

Prato, PO, 59100, Italy
Ospedale San Luca
RECRUITING

Lucca, LU, 55100, Italy
Ospedale San Raffaele
RECRUITING

Milan, MI, 20132, Italy
Policlinico Universitario Tor Vergata
RECRUITING

Rome, 00133, Italy
U.O. Oncologia Medica 2 Universitaria - Azienda Ospedaliero-Universitaria Pisana Dipartimento di Ricerca Traslazionale e Nuove Tecnologie - University of Pisa
RECRUITING

Pisa, 56126, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.